Analyst Reco. AbbVie Inc. London S.E.

Equities

0QCV

US00287Y1091

Real-time Estimate Cboe BZX Other stock markets 14:38:13 05/07/2024 BST			5-day change	1st Jan Change
164.5 ^USD	-0.10%		-2.84%	+6.95%

03:26pm	Sector Update: Health Care Stocks Steady Premarket Friday	MT
09:59am	AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Price Target on AbbVie to $190 From $185	06-18	MT
AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer	06-14	MT
HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $185 From $161	06-05	MT
ANALYST RECOMMENDATIONS : Abbvie, Air Products, Applied Materials, KLA Corporation, UnitedHealth...	06-05
Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	05-17	MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...	05-17
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190	05-08	MT
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	04-29	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	04-29	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	04-29	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	04-19	MT
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	03-27	MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	03-22	MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing	03-21	MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	03-15
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	02-26
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	02-15	MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating	02-06	MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating	02-06	MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating	02-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AbbVie Inc. London S.E.

Equities

0QCV

US00287Y1091

Analyst Reco.

Filters